---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-103097"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2024-09-04T23:59:59+00:00"
generated_at: "2026-05-31T06:24:02.824619+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# EyePoint Pharma appoints Fred Hassan to board; directors Guyer, Adamis resign for Merck roles

## Summary
- David Guyer and Anthony Adamis resigned from board effective Sept 3, 2024 due to full-time roles at Merck & Co.
- Fred Hassan appointed to board; board size reduced from 9 to 8 members.
- Hassan received option grant for 60,000 shares vesting over 3 years, annual cash retainer $45k.
- Karen Zaderej and Stuart Duty join Compensation Committee (Zaderej as Chair); Hassan joins Governance Committee.
- Company nearing first patient dosing in Phase 3 LUGANO trial of DURAVYU for wet AMD.

## SEC filing metadata
- accession: 0000950170-24-103097
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2024-09-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/eypt-20240903.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-103097
- JSON: https://secwatch.observer/filing/0000950170-24-103097.json
- Plain text: https://secwatch.observer/filing/0000950170-24-103097.txt

## Key facts
- Executive change
  Fred Hassan was appointed as Director at EyePoint, Inc..
  - Action: appointed
  - Role: Director
  source text: the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the "Governance and Nominating Committee"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm
- Executive change
  David R. Guyer resigned as Director at EyePoint, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm
- Executive change
  Anthony P. Adamis resigned as Director at EyePoint, Inc..
  - Action: resigned
  - Role: Director
  source text: On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1314102/000095017024103097/0000950170-24-103097-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.